Fondaparinux Sodium

磺达肝癸钠

Report date: 2026/05/08 20:02:52
NME

Base Information

Drug NameFondaparinux Sodium
Drug Alias Name磺达肝素钠Fondaparinuxum natricumFondaparinux sodique磺达肝葵钠Xantidar +[12] 
ClassificationSmall molecules > Carbohydrate
Mechanisms of ActionAntithrombin-III activatorsFactor Xa inactivationThrombin inactivation
TargetsAntithrombin-IIIProthrombinCoagulation factor X
Therapy Area/IndicationsObesity, MorbidVenous ThrombosisThrombosis +[13] 
Global Approved IndicationsVenous ThrombosisThromboembolismMyocardial Infarction +[6] 
Approved Indications in ChinaVenous ThrombosisThromboembolismMyocardial Infarction +[4] 
Original Approved Country/TerritoryUnited States
Original Approved Date2001/12/07
Country/TerritoryCzechiaBulgariaCanada +[22] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesOrganon
China Registration ClassN/A

Develop Information

Active CompaniesGlaxo Wellcome Production SasViatris Healthcare LtdGlaxosmithkline Plc +[4] 
Inactive CompaniesOrganonSchering-PloughEastern Virginia Medical School +[10] 
Active IndicationsVenous ThrombosisThromboembolismMyocardial Infarction +[6] 
Inactive IndicationsObesity, MorbidThrombosisVenous Thromboembolism +[7] 

Other Information

ATC CodeB01AX05
Related LinksWikipediaDrugBankKEGG